Radosław Kempiński

Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial

Brian G. Feagan, Silvio Danese, Edward V. Loftus et al. · The Lancet · 2021 · 437 citations

Medicine, Clinical Sciences, Pharmacotherapy +15

Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis

Bruce E. Sands, Brian G. Feagan, Laurent Peyrin‐Biroulet et al. · New England Journal of Medicine · 2024 · 72 citations

Life Sciences, Immunology, Oncology +17

ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension

Séverine Vermeire, Bruce E. Sands, Herbert Tilg et al. · ˜The œLancet. Gastroenterology & hepatology · 2022 · 64 citations

Medicine, Clinical Sciences, Pharmacology +14

Transcriptional and Metabolomic Analysis of L-Arginine/Nitric Oxide Pathway in Inflammatory Bowel Disease and Its Association with Local Inflammatory and Angiogenic Response: Preliminary Findings

Małgorzata Krzystek‐Korpacka, Mariusz G. Fleszar, Iwona Bednarz‐Misa et al. · International Journal of Molecular Sciences · 2020 · 50 citations · Full text

Life Sciences, Biochemistry, Immunology +17

L-Arginine/Nitric Oxide Pathway Is Altered in Colorectal Cancer and Can Be Modulated by Novel Derivatives from Oxicam Class of Non-Steroidal Anti-Inflammatory Drugs

Małgorzata Krzystek‐Korpacka, Berenika M. Szczęśniak-Sięga, Izabela Szczuka et al. · Cancers · 2020 · 35 citations · Full text

Medicine, Oncology, Pharmacology +16